PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.
The user switched from finasteride to dutasteride and started oral minoxidil, experiencing continuous hair shedding for 7-8 months, which is longer than expected. They are considering switching back to finasteride due to the persistent shedding.
The conversation humorously discusses hair loss treatments like finasteride and minoxidil, noting minoxidil's toxicity to cats. It jokes about a lion needing hair restoration, with references to hair transplants in Turkey.
Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.
A 38-year-old man is using topical and oral Minoxidil, DHT blocker shampoo, and microneedling for hair regrowth, with plans to add Finasteride later. Many users suggest starting Finasteride or Dutasteride immediately to address the root cause of hair loss, while some express concerns about potential side effects.
The user has been using finasteride for 5 months and minoxidil for 9 months without results and is considering switching to dutasteride. Microneedling seems to be the only effective treatment for them so far.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
The user has been taking 0.25mg of oral finasteride daily for a month and is considering increasing the dose to 1/3 of a pill. They have also been using topical minoxidil for several years.
The user is updating on their hair loss treatment progress after 4 months using oral finasteride, topical minoxidil spray, and weekly 1mm dermarolling. The crown area is slowly improving, with a smaller bald spot radius compared to the previous month.